Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NeurAxis, Inc. (NRXS)
USD6.98
-0.17 (-2.38%)
US AMEX Healthcare Biotechnology
Address
11550 North Meridian Street 46032
Carmel, IN, US
Carmel, IN, US
CEO
Brian Carrico
Website
neuraxis.com
IPO
2023-08-09
CIK 1933567 ISIN US64134X2018
Description
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.98
-0.17 (-2.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
148.4K
Beta
1.41
Float Shares
7.66M
Free Float %
66.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.47% | -6.66% | +20.91% | +70.52% | +218.08% | +82.16% | +256.47% | +37.83% | +37.83% | +37.83% | +37.83% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
6.98
Low
8.00
+14.6%
Consensus
8.00
+14.6%
Median
8.00
+14.6%
High
8.00
+14.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
7.50
+7.4%
|
| All Time | 2 |
7.50
+7.4%
|
Quality scores
Altman Z-Score
6.65
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+32.9% ★ Q1'26: +79.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+22.1% Q1'26: +45.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-200.7% Q1'26: -76.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-216.5% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+31.3% Q1'26: +46.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
2.46M
est: 3.66M (-32.7%)
|
2.69M
est: 11.65M (-77.0%)
|
3.57M
est: 3.45M (+3.4%)
|
9.60M
9.00M – 10.20M
+178.2% YoY
|
20.70M
20.29M – 21.11M
+115.6% YoY
|
32.80M
32.15M – 33.45M
+58.5% YoY
|
| EBITDA |
-9.23M
est: -3.66M (-152.5%)
|
-7.90M
est: -11.65M (+32.2%)
|
-7.67M
est: -3.45M (-122.2%)
|
-9.60M
-10.20M – -9.00M
-178.2% YoY
|
-20.70M
-21.11M – -20.29M
-115.6% YoY
|
-32.80M
-33.45M – -32.15M
-58.5% YoY
|
| EBIT |
-9.27M
est: -3.66M (-153.6%)
|
-7.94M
est: -11.65M (+31.9%)
|
-7.73M
est: -3.45M (-123.9%)
|
-9.60M
-10.20M – -9.00M
-178.2% YoY
|
-20.70M
-21.11M – -20.29M
-115.6% YoY
|
-32.80M
-33.45M – -32.15M
-58.5% YoY
|
| Net Income |
-14.63M
|
-8.24M
est: -908.3K (-807.3%)
|
-7.80M
est: -9.08M (+14.1%)
|
-5.04M
-6.05M – -4.03M
+44.5% YoY
|
-272.5K
-279.5K – -265.5K
+94.6% YoY
|
3.54M
3.45M – 3.63M
+1,400.0% YoY
|
| SGA |
8.65M
est: 10.00M (-13.5%)
|
9.27M
est: 32.10M (-71.1%)
|
10.34M
est: 9.51M (+8.8%)
|
26.45M
24.79M – 28.10M
+178.2% YoY
|
57.02M
55.89M – 58.15M
+115.6% YoY
|
90.36M
88.57M – 92.15M
+58.5% YoY
|
| EPS |
-2.32
|
-1.22
est: -0.10 (-1,120.0%)
|
-0.95
est: -1.00 (+5.0%)
|
-0.56
-0.67 – -0.44
+44.5% YoY
|
-0.03
-0.03 – -0.03
+94.6% YoY
|
0.39
0.38 – 0.40
+1,400.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.38M
OE per share TTM
-0.74
Owner's Yield
-8.61%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
10.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
1
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | P. Hannasch | 695.8K | 10.20% | 695.8K | — | 695.8K | — | IN | United States | 2024-10-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 209.6K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 722.8K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.5K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 9.6K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 709.85 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.64M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.6K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.0K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 791.48 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 87.25 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
250.5K
Shares disposed
—
Cash buys
3.00
Cash sales
—
Net activity
+250,541
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Aharon Gil | Director | A-Award | A | Common Stock | 221,917 | 0.00 | — | 508,055 | I | ↗ |
| 2026-04-01 | Henrichs Timothy Robert | Officer | P-Purchase | A | Common Stock | 7,593 | 1.96 | 14.9K | 7,593 | D | ↗ |
| 2026-04-01 | Carrico Thomas Joeseph | Officer | P-Purchase | A | Common Stock | 667 | 1.96 | 1.3K | 331,903 | D | ↗ |
| 2026-04-01 | Carrico Brian Allen | Director / Officer | P-Purchase | A | Common Stock | 8,060 | 1.96 | 15.8K | 348,178 | D | ↗ |
| 2026-01-22 | Watkins Bradley Mitchell | Director | A-Award | A | Common Stock | 21,598 | 4.63 | 100.0K | 46,335 | D | ↗ |
| 2026-01-22 | Miranda Adrian | Officer | A-Award | A | RSU | 47,569 | 0.00 | — | 47,569 | D | ↗ |
| 2026-01-22 | Keyser Jane Elizabeth | Director | A-Award | A | Common Stock | 21,598 | 4.63 | 100.0K | 46,335 | D | ↗ |
| 2026-01-22 | Henrichs Timothy Robert | Officer | A-Award | A | RSU | 75,231 | 0.00 | — | 75,231 | D | ↗ |
| 2026-01-22 | Ferge Kristin A | Director | A-Award | A | Common Stock | 21,598 | 4.63 | 100.0K | 35,938 | D | ↗ |
| 2026-01-22 | Carrico Thomas Joeseph | Officer | A-Award | A | RSU | 47,569 | 0.00 | — | 47,569 | D | ↗ |
| 2026-01-22 | Carrico Brian Allen | Director / Officer | A-Award | A | RSU | 94,173 | 0.00 | — | 94,173 | D | ↗ |
| 2026-01-22 | Aharon Gil | Director | A-Award | A | Common Shares | 21,598 | 4.63 | 100.0K | 307,736 | D | ↗ |
| 2025-12-23 | Aharon Gil | Director | P-Purchase | A | Common Shares | 286,138 | 3.52 | 1.01M | 286,138 | I | ↗ |
| 2025-07-01 | MASIMO CORP | 10% Owner | C-Conversion | A | Common Stock | 289,779 | 0.00 | 28.98 | 289,779 | D | ↗ |
| 2025-03-18 | Henrichs Timothy Robert | Officer | A-Award | A | RSU | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2025-03-04 | Miranda Adrian | Officer | A-Award | A | RSU | 30,000 | 0.00 | — | 30,000 | D | ↗ |
| 2025-03-04 | Henrichs Timothy Robert | Officer | A-Award | A | RSU | 66,000 | 0.00 | — | 66,000 | D | ↗ |
| 2025-03-04 | Carrico Thomas Joeseph | Officer | A-Award | A | RSU | 27,435 | 0.00 | — | 27,435 | D | ↗ |
| 2025-03-04 | Carrico Brian Allen | Director / Officer | A-Award | A | RSU | 10,000 | 0.00 | — | 10,000 | D | ↗ |
| 2025-01-17 | Watkins Bradley Mitchell | Director | A-Award | A | Common Stock | 13,157 | 2.85 | 37.5K | 24,737 | D | ↗ |
| 2025-01-17 | Keyser Jane Elizabeth | Director | A-Award | A | Common Stock | 13,157 | 2.85 | 37.5K | 24,737 | D | ↗ |
| 2025-01-17 | Ferge Kristin A | Director | A-Award | A | Common Stock | 13,157 | 2.85 | 37.5K | 14,340 | D | ↗ |
| 2025-01-03 | Miranda Adrian | Officer | A-Award | A | RSU | 35,000 | 0.00 | — | 35,000 | D | ↗ |
| 2025-01-03 | Henrichs Timothy Robert | Officer | A-Award | A | RSU | 67,980 | 0.00 | — | 67,980 | D | ↗ |
| 2025-01-03 | Carrico Thomas Joeseph | Officer | A-Award | A | RSU | 35,000 | 0.00 | — | 35,000 | D | ↗ |
| 2025-01-03 | Carrico Brian Allen | Director / Officer | A-Award | A | RSU | 70,019 | 0.00 | — | 70,019 | D | ↗ |
| 2024-11-25 | Aharon Gil | Director | — | — | Series B Convertible Preferred Stock | 1,890,756 | 2.38 | 4.50M | 0 | I | ↗ |
| 2023-08-08 | SEALE JOHN G | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-3.7K
Shares Outstanding
11.51M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Brian Carrico Chief Executive Officer | 345.1K | 181.0K | 388.8K | — | — | — | 936.4K | 41.52% | ↗ |
| 2 | 2025 | Timothy Henrichs Chief Financial Officer | 327.3K | 140.6K | 327.9K | — | — | — | 817.3K | 40.12% | ↗ |
| 3 | 2025 | Dr. Adrian Miranda Chief Medical Officer | 300.0K | 77.5K | 171.9K | — | — | — | 571.0K | 30.11% | ↗ |
| 4 | 2025 | Dr. Thomas Carrico Chief Regulatory Officer | 300.0K | 77.5K | 166.3K | — | — | — | 566.9K | 29.34% | ↗ |
| 5 | 2024 | Timothy Henrichs Chief Financial Officer | 274.1K | 112.2K | 227.0K | — | — | — | 628.9K | 36.10% | ↗ |
| 6 | 2024 | Brian Carrico Chief Executive Officer | 353.0K | 206.7K | — | — | — | — | 578.4K | 0.00% | ↗ |
| 7 | 2024 | Dr. Adrian Miranda Chief Medical Officer | 300.0K | 63.8K | — | — | — | — | 382.4K | 0.00% | ↗ |
| 8 | 2024 | Dr. Thomas Carrico Chief Regulatory Officer | 288.3K | 63.8K | — | — | — | — | 368.9K | 0.00% | ↗ |
| 9 | 2023 | Brian Carrico Chief Executive Officer | 375.0K | 441.3K | — | — | — | — | 839.4K | 0.00% | ↗ |
| 10 | 2023 | Dr. Thomas Carrico Chief Regulatory Officer | 278.8K | 116.7K | — | — | — | — | 411.1K | 0.00% | ↗ |
| 11 | 2023 | Dr. Adrian Miranda Chief Medical Officer | 300.0K | — | — | — | — | — | 323.1K | 0.00% | ↗ |
| 12 | 2022 | Brian Carrico Chief Executive Officer | 373.6K | — | — | — | — | 18.6K | 392.2K | 0.00% | ↗ |
| 13 | 2022 | Dr. Thomas Carrico Chief Regulatory Officer | 272.0K | — | — | — | — | 15.2K | 287.2K | 0.00% | ↗ |
| 14 | 2022 | Dr. Adrian Miranda Chief Medical Officer | 266.3K | — | — | — | — | 18.6K | 284.9K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian Carrico | President, Chief Executive Officer & Director | 547.6K | male |
| Timothy Robert Henrichs | Chief Financial Officer | 489.4K | male |
| Thomas Carrico | Chief Regulatory Officer and Compliance & Privacy Officer | 400.6K | male |
| Adrian Miranda | Senior Vice President of Science & Technology and Chief Medical Officer | 399.1K | — |
| Behnam Shamsian | Investor Relations | — | male |
| Christopher Robin Brown | Founder, Director of Innovation & Director | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NRXS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
